Induction of β-defensins by l-isoleucine as novel immunotherapy in experimental murine tuberculosis

Clinical and Experimental Immunology

Volumn 164, Issue 1, 2011, Pages 80-89

  Rivas Santiago, C E ^a,b   Rivas Santiago, B ^c   Leon D A ^a   Castaneda Delgado J ^c   Hernandez Pando R ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Anti microbial peptides; Defensins; l isoleucine; Therapy; Tuberculosis

Indexed keywords

BETA DEFENSIN 3; BETA DEFENSIN 4; GAMMA INTERFERON; ISOLEUCINE; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INFECTION CONTROL; LUNG TUBERCULOSIS; MALE; MORPHOMETRICS; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE INJURY;

ANIMALS; BETA-DEFENSINS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; ISOLEUCINE; LUNG; MALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 79952508380     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04313.x     Document Type: Article

References (38)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677-86.
2. Lonnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008; 29:481-91.
3. Mitnick CD, Appleton SC, Shin SS. Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med 2008; 29:499-524.
4. Rivas-Santiago B, Schwander SK, Sarabia C etal.Human {beta}-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun 2005; 73:4505-11.
5. Korbel DS, Schneider BE, Schaible UE. Innate immunity in tuberculosis: myths and truth. Microbes Infect 2008; 10:995-1004.
6. van Crevel R, Ottenhoff TH, van der Meer JW. Innate immunity to Mycobacterium tuberculosis. Adv Exp Med Biol 2003; 531:241-7.
7. Rivas-Santiago B, Sada E, Hernandez-Pando R, Tsutsumi V. [Antimicrobial peptides in the innate immunity of infectious diseases]. Salud Publica Mex 2006; 48:62-71.
8. Suzuki T, Chow CW, Downey GP. Role of innate immune cells and their products in lung immunopathology. Int J Biochem Cell Biol 2008; 40:1348-61.
9. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. Cell Mol Life Sci 2006; 63:1294-313.
10. Rivas-Santiago B, Contreras JC, Sada E, Hernandez-Pando R. The potential role of lung epithelial cells and beta-defensins in experimental latent tuberculosis. Scand J Immunol 2008; 67:448-52.
11. Rivas-Santiago B, Hernandez-Pando R, Carranza C etal. Expression of cathelicidin LL-37 during Mycobacterium tuberculosis infection in human alveolar macrophages, monocytes, neutrophils, and epithelial cells. Infect Immun 2008; 76:935-41.
12. Rivas-Santiago B, Sada E, Tsutsumi V, Aguilar-Leon D, Contreras JL, Hernandez-Pando R. Beta-defensin gene expression during the course of experimental tuberculosis infection. J Infect Dis 2006; 194:697-701.
13. Bowdish DM, Davidson DJ, Scott MG, Hancock RE. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 2005; 49:1727-32.
14. Funderburg N, Lederman MM, Feng Z etal. Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 2007; 104:18631-5.
15. Yang D, Chertov O, Bykovskaia SN etal. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286:525-8.
16. Ganz T. Defensins: antimicrobial peptides of vertebrates. C R Biol 2004; 327:539-49.
17. Ganz T. Defensins and other antimicrobial peptides: a historical perspective and an update. Comb Chem High Throughput Screen 2005; 8:209-17.
18. Sherman H, Chapnik N, Froy O. Albumin and amino acids upregulate the expression of human beta-defensin 1. Mol Immunol 2006; 43:1617-23.
19. Oppenheim JJ, Biragyn A, Kwak LW, Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis 2003; 62 (Suppl. 2):ii17-21.
20. Menendez A, Brett Finlay B. Defensins in the immunology of bacterial infections. Curr Opin Immunol 2007; 19:385-91.
21. Fehlbaum P, Rao M, Zasloff M, Anderson GM. An essential amino acid induces epithelial beta-defensin expression. Proc Natl Acad Sci USA 2000; 97:12723-8.
22. Welling MM, Hiemstra PS, van den Barselaar MT etal. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J Clin Invest 1998; 102:1583-90.
23. Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Madrid-Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. Immunology 1997; 90:607-17.
24. Hernandez-Pando R, Orozcoe H, Sampieri A etal. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 1996; 89:26-33.
25. Jarnagin JL, Luchsinger DW. The use of fluorescein diacetate and ethidium bromide as a stain for evaluating viability of mycobacteria. Stain Technol 1980; 55:253-8.
26. Sharma S, Verma I, Khuller GK. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur Respir J 2000; 16:112-17.
27. Sharma S, Verma I, Khuller GK. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob Agents Chemother 2001; 45:639-40.
28. Durr M, Peschel A. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect Immun 2002; 70:6515-17.
29. Biragyn A, Ruffini PA, Leifer CA etal. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298:1025-9.
30. Hancock RE, Brown KL, Mookherjee N. Host defence peptides from invertebrates - emerging antimicrobial strategies. Immunobiology 2006; 211:315-22.
31. Mookherjee N, Hancock RE. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell Mol Life Sci 2007; 64:922-33.
32. Yang D, Liu ZH, Tewary P, Chen Q, de la Rosa G, Oppenheim JJ. Defensin participation in innate and adaptive immunity. Curr Pharm Des 2007; 13:3131-9.
33. Beisswenger C, Bals R. Antimicrobial peptides in lung inflammation. Chem Immunol Allergy 2005; 86:55-71.
34. Beisswenger C, Bals R. Functions of antimicrobial peptides in host defense and immunity. Curr Protein Pept Sci 2005; 6:255-64.
35. Fattorini L, Gennaro R, Zanetti M etal. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Peptides 2004; 25:1075-7.
36. Gera JF, Lichtenstein A. Human neutrophil peptide defensins induce single strand DNA breaks in target cells. Cell Immunol 1991; 138:108-20.
37. Tan BH, Meinken C, Bastian M etal. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol 2006; 177:1864-71.
38. Martineau AR, Newton SM, Wilkinson KA etal. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest 2007; 117:1988-94.